Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Fate Therapeutics, Inc. FATE
$5.01
-$0.24 (-4.85%)
На 18:00, 12 мая 2023
+931.34%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
516518604.00000000
-
week52high
37.13
-
week52low
4.02
-
Revenue
96300000
-
P/E TTM
-2687
-
Beta
1.48477500
-
EPS
-2.71000000
-
Last Dividend
0.00000000
-
Next Earnings Date
01 авг 2023 г. в 10:59
Описание компании
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Needham | Hold | 28 июл 2022 г. | |
| BMO Capital | Outperform | Market Perform | 12 июл 2022 г. |
| BMO Capital | Outperform | Market Perform | 11 июл 2022 г. |
| Baird | Neutral | 03 июн 2022 г. | |
| Piper Sandler | Overweight | Overweight | 23 мая 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 09 сент 2022 г. |
| Citigroup | Buy | Buy | 16 ноя 2022 г. |
| Goldman Sachs | Sell | Sell | 09 янв 2023 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 06 янв 2023 г. |
| EF Hutton | Buy | Buy | 06 янв 2023 г. |
| B of A Securities | Underperform | Buy | 06 янв 2023 г. |
| HC Wainwright & Co. | Neutral | Buy | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| MENDLEIN JOHN | A | 0 | 28461 | 19 янв 2023 г. |
| MENDLEIN JOHN | A | 311231 | 28461 | 19 янв 2023 г. |
| MENDLEIN JOHN | A | 282770 | 36631 | 13 янв 2023 г. |
| Valamehr Bahram | A | 0 | 423 | 12 янв 2023 г. |
| Valamehr Bahram | A | 169340 | 423 | 12 янв 2023 г. |
| MENDLEIN JOHN | A | 246139 | 88048 | 11 янв 2023 г. |
| Valamehr Bahram | D | 168917 | 10917 | 10 янв 2023 г. |
| Wolchko J Scott | D | 385639 | 45907 | 10 янв 2023 г. |
| Chu Yu-Waye | D | 143208 | 7825 | 10 янв 2023 г. |
| Dulac Edward J III | D | 129470 | 7331 | 10 янв 2023 г. |
Новостная лента
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
03 мая 2023 г. в 19:02
Fate Therapeutics (FATE) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.68 per share a year ago.
Fate Therapeutics (FATE) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research
03 мая 2023 г. в 13:41
Fate Therapeutics (FATE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results
GlobeNewsWire
24 апр 2023 г. в 08:00
SAN DIEGO, April 24, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Wednesday, May 3, 2023 at 5:00 PM ET to report its first quarter 2023 financial results and provide a corporate update.
Why Is Fate Therapeutics (FATE) Down 8.9% Since Last Earnings Report?
Zacks Investment Research
30 мар 2023 г. в 12:56
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Zacks Investment Research
27 мар 2023 г. в 09:57
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.